Kindstar Global SUCCESSFULLY LISTED ON HKEX
Latest Update:
16 th July, 2021

Kindstar Globalgene Technology, Inc.. (" Kindstar Global "or the" Company ", stock code: 9960.HK), a leading provider of independent clinical special examination services in China, was listed on the main board of the Stock Exchange of Hong Kong Limited (" SEHK ") today on July 16, 2021.

The global offering of 226,405,000 shares was priced at HK $9.78 each. The net proceeds from the global offering are expected to be approximately HK $2053.6 million (excluding overallotments). The initial offer of shares was heavily oversubscribed, which was approximately 543.03 times the initial offer of 22,640,500 shares available for subscription; The international offering was significantly oversubscribed, representing approximately 13.81 times the total number of shares available under the initial international offering.

The executive director, chairman and chief executive and chief medical officer of Kindstar Global shi-ang huang doctors said: "today, Kindstar Global, listed on the stock exchange around the world, set foot on the stage of international capital, is an important milestone in the company. We in the field of Chinese independent clinical inspection has unique advantages, since it was founded in 2003, Our strategy has focused on clinical examination, Kindstar Global universal has advanced technology platform and comprehensive, combination, the integration of national sales and logistics network, and has strong research and development of proprietary and business development capabilities to promote continuous incremental innovation. In the future, we will continue to consolidate the leading position in the Chinese blood epidemiology, clinical inspection, And copy our success in haematology, experience, speed up the growth of other specialist areas; to migrate across industry value chain, we will also promote the competitiveness of the business, and will detect footprint to expand to the world, committed to providing patients and doctors wide and high quality specialized testing service, further promote the application of precision medical."

About Kindstar Globalgene Technology, Inc.

Kindstar Global is a leading provider of independent clinical examination services in China. Kindstar Global has the largest independent independent counsel portfolio in China, offering over 3,500 tests on its service list, including over 2,300 hematology tests. More than 1,100 inspection items were developed entirely in-house, and about 2,400 were developed or licensed from third parties. We provide a full range of testing services in hematology, genetic and rare diseases, infectious diseases, tumors, neurology and gynecology related diseases.

Latest Update:
16 th July, 2021